Bibliography
- Pellegrini F, Budman DR. Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest 2005;23:264-73
- Sengupta S, Thomas SA. Drug target interaction of tubulin-binding drugs in cancer therapy. Expert Rev Anticancer Ther 2006;6:1433-47
- Hait WN, Rubin E, Alli E, et al. Tubulin targeting agents. Update Cancer Ther 2007;2:1-18
- Altmann KH, Gertsch J. Anticancer drugs from nature-natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep 2007;24:327-57
- Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic – thirteenth Bruce F. Cain Memorial Award Lecture. Cancer Res 1995;55:753-60
- Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979;277:665-7
- Searchable website for ongoing clinical trials. Available from: http://clinicaltrials.gov/
- Emerson DL, Jones M, Bell C, et al. TPI 287 crosses the blood brain barrier and contributes to antitumor activity in the U251 glioblastoma intracranial tumor model in nude mice [poster 1441]. American Association for Cancer Research Annual Meeting: Proceedings; 2007
- Jones ME, Barrett BS, Bell C, et al. TPI 287, a next generation taxane derivative, functionally modulates MDR1 P-glycoprotein drug transport pump and is active in resistant tumor cells [poster A192]. AACR-NCI-EORTC International Meeting, Molecular Targets and Cancer, Therapeutics Meeting; 2007
- Modiano M, Plezia P, Baram J, et al. A phase 1 study OF TPI 287 – a third generation taxane administered every 21 days in patients with advanced cancer. J Clin Oncol 2007;25:2569
- Hwang J, Marshall J, Ahmed T, et al. A phase 1 study of TPI 287, a third generation taxane administered weekly in patients with advanced cancer. J Clin Oncol 2007;25:2575
- Tapestry Pharmaceuticals website-therapeutics-taxanes. Available from: http://www.tapestrypharma.com/therapeutics/taxanes/at
- Brahmer JR, Shapiro M, Carducci K, et al. Phase I trial of a potent novel taxane, TL(0013)9 (MAC-321), in patients with advanced malignant solid tumors. Proc Am Soc Clin Oncol 2003;22:2003
- Lockhart AC, Bukowski R, Rothenberg ML, et al. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors. Cancer Chemother Pharmacol 2007;60:203-9
- Sampath D, Discafani CM, Loganzo F, et al. MAC-321, a novel taxane with greater efficacy than paclitaxel and docetaxel in vitro and in vivo. Mol Cancer Ther 2003;2:873-84
- Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther 2006;5:270-8
- Larkin JM, Kaye SB. Epothilones in the treatment of cancer. Expert Opin Investig Drugs 2006;15:691-702
- Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist 2007;12:271-80
- Larkin JM, Kaye SB. Potential clinical applications of epothilones: a review of phase II studies. Ann Oncol 2007;5:v28-34
- Gerth K, Bedorf N, Hofle G, et al. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria): production, physico-chemical and biological properties. J Antibiot (Tokyo) 1996;49:560-3
- Kowalski RJ, Giannakakou P, Hamel E. Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)). J Biol Chem 1997;272:2534-41
- Hofstetter B, Van Vuong V, Broggini-Tenzer A, et al. Patupilone acts as radiosensitizing agent in multidrug-resistant cancer cells in vitro and in vivo. Clin Cancer Res 2005;11:1588-96
- Lee FY, Borzilleri R, Fairchild CR, et al. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res 2001;7:1429-37
- Giannakakou P, Gussio R, Nogales E, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA 2000;97:2904-9
- Bollag DM, McQueney PA, Zhu J, et al. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res 1995;55:2325-33
- Fojo T, Menefee M. Mechanisms of multidrug resistance: the potential role of microtubule-stabilizing agents. Ann Oncol 2007;18(Suppl 5):v3-8
- Bauer B, Hartz AM, Fricker G, Miller DS. Modulation of p-glycoprotein transport function at the blood-brain barrier. Exp Biol Med (Maywood) 2005;230:118-27
- Kusuhara H, Sugiyama Y. Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2005;2:73-85
- Löscher W, Potschka H. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2005;2:86-98
- Lerzo GL, Lee RK, Thomas ES, et al. Phase III study of ixabepilone plus capecitabine in metastatic breast cancer (MBC) progressing after anthracyclines and taxanes: Subgroup analysis in HER2+ disease. J Clin Oncol 2007;25:152
- Pivot XB, Lee RK, Thomas ES, et al. Phase III study of ixabepilone plus capecitabine in patients with metastatic breast cancer (MBC) resistant to anthracyclines/taxanes: subgroup analysis by estrogen receptor (ER) status. J Clin Oncol 2007;25:221
- The ixabepilone label. Available from: http://www.fda.gov/cder/foi/label/2007/022065lbl.pdf
- Moulder SL, Wang M, Gradishar W, et al. A phase II trial of trastuzumab, weekly ixabepilone and carboplatin (TIC) in patients with HER2/neu-positive (HER2+) metastatic breast cancer (MBC): a trial coordinated by the Eastern Cooperative Oncology Group (E2103). J Clin Oncol 2007;25:152
- Hsin KW, Boyer M, Ducreux M, et al. Efficacy of patupilone in advanced local or metastatic gastric cancer: a phase IIa trial. J Clin Oncol 2006;24:4069
- Venook AP, Poon R, Kang YK, et al. Evaluation of patupilone as monotherapy in patients with advanced hepatocellular carcinoma (HCC). J Clin Oncol 2007;25:15055
- Abrey L, Wen PY, Govindan R, et al. Activity of patupilone for the treatment of recurrent or progressive brain metastases in patients (pts) with non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II study. J Clin Oncol 2007;25:18058
- Rustin GJ, Reed NS, Jayson G, et al. Phase II trial of the novel epothilone ZK-EPO in patients with platinum resistant ovarian cancer. J Clin Oncol 2007;25:5527
- Stopeck A, Moulder S, Jones S, et al. Optimization of the phase 2 dose of KOS-1584 (a novel, synthetic epothilone) via weekly administration [abstract no. A286]. AACR-NCI-EORTC – 19th Symposium Molecular Targets and Cancer Therapeutics; 2007
- Villalona-Calero M, Goel S, Schaaf L, et al. First-in-human phase I trial of a novel epothilone, KOS-1584. J Clin Oncol 2006;24:2003
- Denekamp J. Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy. Br J Radiol 1993;66:181-96
- Bloemendal HJ, Logtenberg T, Voest EE. New strategies in anti-vascular cancer therapy. Eur J Clin Invest 1999;29:802-9
- Hinnen P, Eskens F. Vascular disrupting agents in clinical development. Br J Cancer 2007;96:1159-65
- Bennouna J, Campone M, Delord JP, et al. Vinflunine: a novel antitubulin agent in solid malignancies. Expert Opin Investig Drugs 2005;14:1259-67
- Hill BT. Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers. Curr Pharm Des 2001;7:1199-212
- Holwell SE, Hill BT, Bibby MC. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. Br J Cancer 2001;84:290-5
- Goldstein D, Ackland SP, Bell DR, et al. Phase II study of vinflunine in patients with metastatic renal cell carcinoma. Invest New Drugs 2006;24:429-34
- Olver IN, Byrne MJ, Walpole E, et al. Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma. Eur J Cancer 2007;43:1829-32
- Peyton JD, Spigel DR, Hainsworth JD, et al. Phase II trial of vinflunine in patients with relapsed small cell lung cancer. J Clin Oncol 2007;25:18091
- Talbot D, Margery J, Dabouis G, et al. Phase II study of vinflunine in malignant pleural mesothelioma. J Clin Oncol 2007;25:4751-6
- Bennouna J, Breton JL, Tourani JM, et al. Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study. Br J Cancer 2006;94:1383-8
- Campone M, Cortes-Funes H, Vorobiof D, et al. Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline/taxane-based chemotherapy. Br J Cancer 2006;95:1161-6
- Peacock NW, Spigel DR, Mainwaring MG, et al. Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer. J Clin Oncol 2007;25:1043
- Krzakowski M, Douillard J, Ramlau R, et al. Phase III study of vinflunine versus docetaxel in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with a platinum-containing regimen. J Clin Oncol 2007;25:7511
- Seed L, Slaughter DP, Limarzi LR. Effect of colchicine on human carcinoma. Surgery 1940;7:696-709
- Pettit GR, Singh SB, Niven ML, et al. Isolation, structure and synthesis of combretastatins A-1 and B-1, potent new inhibitors of microtubule assembly, derived from Combretum caffrum. J Nut Prod 1987;50:119-31
- Pettit GR, Singh SB, Hamel E, et al. Isolation and structure of the strong cell growth and tubulin inhibitor Combretastatin A-4. Experientia 1989;45:209-11
- Chaplin DJ, Pettit GR, Parkins CS, et al. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer Suppl 1996;27:S86-8
- Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2001;2:82-7
- Bilenker JH, Flaherty KT, Rosen M. Phase I trial of combretastatin a-4 phosphate with carboplatin. Clin Cancer Res 2005;11:1527-33
- Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002;62:3408-16
- Stevenson JP, Rosen M, Sun W, et al. Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow. J Clin Oncol 2003;21:4428-38
- Anderson HL, Yap JT, Miller MP. Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate. J Clin Oncol 2003;21:2823-30
- Rustin GJS, Galbraith SM, Anderson H, et al. Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results. J Clin Oncol 2003;21:2815-22
- Salmon HW, Siemann DW. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clin Cancer Res 2006;12:4090-4
- Patterson DM, Ross P, Koetz B, et al. Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumours. J Clin Oncol 2007;25:14146
- Hori K. Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700). Chemotherapy 2005;51:357-60
- Tolcher AW, Forero L, Celio P, et al. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days [abstract 834]. Proc Am Soc Clin Oncol 2003;22
- Santoni J. Sanofi-aventis' late stage R&D pipeline 2007. sanofi aventis website. Available from: http://www.sanofi-aventis.com/Images/20070510_exane_en_tcm23-17719.pdf
- Jordan M, Kamath K, Manna T. The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth. Mol Cancer Ther 2005;4:1086-95
- Dabydeen DA, Burnett JC, Bai R. Comparison of the activities of the truncated halichondrin B analog NSC 707389 (E7389) with those of the parent compound and a proposed binding site on tubulin. Mol Pharmacol 2006;70:1866-75
- Kuznetsov G, Tendyke K, Yu MJ, et al. C58 Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro [abstract no. C58]. AACR-NCI-EORTC – 19th Symposium Molecular Targets and Cancer Therapeutics; 2007
- Blum JL, Pruitt BT, Fabian CJ, et al. Phase II study of eribulin mesylate (E7389) in patients with heavily pretreated advanced breast cancer [abstract no. 223]. Breast Cancer Symposium (ASCO); 2007
- Spira AI, Iannotti NO, Savin MA, et al. Phase II study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2007;25:7546
- Molife R, Cartwright TH, Loesch DM, et al. Phase II multicenter, two-stage study of E7389 in patients with hormone refractory prostate cancer with advanced and/or metastatic disease stratified by prior chemotherapy. J Clin Oncol 2007;25:15513
- Garg V, Zhang W, Gidwani P, et al. Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma. Clin Cancer Res 2007;13:5446-54
- Bai R, Durso NA, Sackett DL, et al. Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1. Biochemistry 1999;38:14302-10
- Otani M, Natsume T, Watanabe JI, et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res 2000;91:837-44
- Aguayo A, Kraut E, Moore D, et al. Administered intravenously every 21 days to patients (pts) with metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 2000;19:1127
- Margolin K, Longmage J, Gandara D, et al. Dolastatin-10 (DOLA) in metastatic melanoma (MEL): a phase II Trial of the California Cancer Consortium. Proc Am Soc Clin Oncol 2000;9:2243
- McDermott DF, Hersh E, Weber J, et al. ILX651 administered daily for five days every 3 weeks (qdx5dq3w) in patients (pts) with inoperable locally advanced or metastatic melanoma: phase II experience. J Clin Oncol 2007;23:7556
- Genzyme website-Tasidotin hydrochloride. Available from: http://www.genzymeoncology.com/onc/research/onc_p_research.asp
- Lakhani NJ, Sarkar MA, Venitz J, et al. 2-Methoxyestradiol, a promising anticancer agent. Pharmacotherapy 2003;23:165-72
- Klauber N, Parangi S, Flynn E, et al. Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 1997;57:81-6
- Schumacher G, Kataoka M, Roth JA, et al. Potent antitumor activity of 2-methoxyestradiol in human pancreatic cancer cell lines. Clin Cancer Res 1999;5:493-9
- Keck C, Schürle C, Pietrowski D, et al. Growth inhibiting effects of progesterone, 17beta-estradiol and 2-methoxyestradiol on human endothelial cells. J Turk Germ Gynecol Assoc 2006;7:11-7
- Dahut WL, Lakhani NJ, Gulley JL, et al. Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors. Cancer Biol Ther 2006;5:22-7
- James J, Murry D, Treston A, et al. Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 2007;25:41-8
- Lacy M, Richardson P, Gertz M, et al. Novel therapy with 2-methoxyestradiol (2ME2) for the treatment of relapsed and plateau phase multiple myeloma. J Clin Oncol 2007;25:8108
- Sweeney C, Glenn Liu G, Yiannoutsos C, et al. A phase II multicenter, randomized, double-blind, safety trial assessing the pharmacokinetics, pharmacodynamics, and efficacy of oral 2-methoxyestradiol capsules in hormone-refractory prostate cancer. Clin Cancer Res 2005;11:6625-33
- Matei D, Schilder J, Menning N, et al. Phase II open-label, safety, pharmacokinetic and efficacy study of Panzem® NCD administered orally to patients with ovarian cancer [poster A14]. AACR-NCI-EORTC International Meeting, Molecular Targets and Cancer, Therapeutics meeting; 2007
- EntreMed website-ENMD-1198 for Oncology. Available from: http://www.entremed.com/science/enmd-1198/
- Liaw TT, Lavallee T, Lock R, et al. ENMD-1198: a microtubule destabilizing agent active against drug resistant leukemia cell lines and human leukemia xenografts [abstract 1439]. American Association for Cancer Research Annual Meeting: Proceedings; 2007;48
- Kuznetsov G, Tendyke K, Towle MJ, et al. In vitro and in vivo antitumor activities of novel hemiasterlin analog E7974 [abstract 3432]. Association for Cancer Research Annual Meeting: Proceedings; 2005;46
- Madajewicz S, Zojwalla NJ, Lucarelli AG, et al. A phase I trial of E7974 administered on days 1 and 15 of a 28-day cycle in patients with solid malignancies. J Clin Oncol 2007;25:2550
- Zojwalla NJ, Takimoto CH, Lucarelli AG, et al. A phase I trial of E7974 administered on days 1, 8, and 15 of a 28-day cycle in patients with solid malignancies. J Clin Oncol 2007;25:2543
- Nicholson B, Lloyd GK, Miller BR, et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anticancer Drugs 2006;17:25-31
- Spear MA, Lorusso P, Tolcher AW, et al. A phase 1 dynamic accelerated titration dose escalation study of the vascular disrupting agent NPI-2358. J Clin Oncol 2007;25:14097
- Yoshimatsu K, Yamaguchi A, Yoshino H, et al. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin. Cancer Res 1997;57:3208-13
- Luo Y, Hradil V, Mohning K, et al. Time-dependent anti-vascular effects of ABT-751 assessed by dynamic contrast enhanced MRI (DCE-MRI). Proc Intl Soc Mag Reson Med 2004;11:545
- Fox E, Maris JM, Widemann BC, et al. A phase 1 study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 7 days every 21 days in pediatric patients with solid tumors. Clin Cancer Res 2006;12:4882-7
- Mauer AM, Szeto L, Belt RJ, et al. Preliminary results of a phase 2 study of ABT-751 in patients (pts) with taxane-refractory non-small cell lung carcinoma (NSCLC). J Clin Oncol 2005;23:7137
- Benson AB, Kindler HL, Jodrell D, et al. Phase 2 study of ABT-751 in patients with refractory metastatic colorectal carcinoma (CRC). J Clin Oncol 2005;23:3537
- Washington DK, Storniolo AV, Saleh M, et al. Phase 2 results of ABT-751 in subjects with taxane-refractory breast cancer: interim analysis. J Clin Oncol 2005;23:724
- Hagey AE, Figlin RA, Moldawer N, et al. Preliminary Phase 2 results of ABT-751 in subjects with advanced renal cell carcinoma (RCC). J Clin Oncol 2005;23:4603
- Kasibhatla S, Baichwal V, Cai SX, et al. MPC-6827: a small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps. Cancer Res 2007;67:5865-71
- Pleiman C, Baichwal V, Bhoite L, et al. Vascular disruption effects of MPC-6827 [abstract no. 1422]. American Association for Cancer Research Annual Meeting: Proceedings; 2007;48
- Kurzrock R, Akerley W, Hong D, et al. Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases. J Clin Oncol 2007;25:3604
- Gerlach M, Schuster T, Teifel M, et al. A novel highly potent cytotoxic compound with inhibitory effects on tubulin polymerization and topopisomerase II [abstract no. 499]. American Association for Cancer Research Annual Meeting: Proceedings; 2006;47
- Æterna Zentaris website-AEZS-112 (ZEN-012). Available from: http://www.aeterna.com/en/page.php?p=31&prod=19 at
- Lickliter J, Smith G, Burge M, et al. Phase I study of CYT997, a novel cytotoxic and vascular disrupting agent, given as a 24-hour intravenous infusion to patients with advanced solid tumours. J Clin Oncol 2007;25:14115
- Ricart AD, Cooney M, Sarantopoulos J, et al. A phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of MN-029, a novel vascular disrupting agent (VDA), in patients (pts) with advanced solid tumors. J Clin Oncol 2006;24:3096
- Anthony SP, Von Hoff D, Whisnant JK, et al. EPC2407, a new beta-tubulin vascular disrupting agent with potent apoptosis and cell growth inhibition. J Clin Oncol 2007;25:14043
- EpiCept website-EpiCept announces successful completion of enrollment for Phase I Trial of EPC2407. Available from: http://investor.epicept.com/releasedetail.cfm?ReleaseID=267755
- Bacher G, Nickel B, Emig P, et al. D-24851, a novel synthetic microtubule inhibitor, exerts curative antitumoral activity in vivo, shows efficacy toward multidrug-resistant tumor cells, and lacks neurotoxicity. Cancer Res 2001;61:392-9
- Raab G, Bacher G, Komarnitsky PB, et al. Indibulin (ZIO-301): a novel tubulin polymerization inhibitor has potent anti tumor activity and a distinct tubulin binding bite [abstract no. B276]. AACR-NCI-EORTC – 19th Symposium Molecular Targets and Cancer Therapeutics; 2007
- Oostendorp RL, Witteveen PO, Schwartz B, et al. Phase I and pharmacological study of orally administered indibulin in advanced solid tumors. J Clin Oncol 2007;25:2565
- Ferretti S, Allegrini PR, O'reilly T, et al. Patupilone induced vascular disruption in orthotopic rodent tumour models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005;11:7773-84